vs
ASTROTECH Corp（ASTC）与Can-Fite BioPharma Ltd.（CANF）财务数据对比。点击上方公司名可切换其他公司
Can-Fite BioPharma Ltd.的季度营收约是ASTROTECH Corp的1.4倍（$202.0K vs $148.0K），Can-Fite BioPharma Ltd.净利率更高（-2413.9% vs -2653.4%，领先239.5%），Can-Fite BioPharma Ltd.同比增速更快（-36.1% vs -43.3%），ASTROTECH Corp自由现金流更多（$-4.0M vs $-4.8M）
航天科技公司（原名Spacehab Inc.）是一家总部位于美国得克萨斯州奥斯汀的科技孵化企业。该公司整合内部、研究机构、政府实验室及高校的技术资源，投资、孵化并退出初创企业，旗下子公司还为美国航空航天局、美国国防部、各国航天机构及全球商业客户提供商业化产品与服务。
Can-Fite BioPharma是一家处于临床阶段的生物制药企业，专注于开发靶向腺苷受体的专利小分子疗法，管线覆盖肿瘤、炎症性疾病、肝脏疾病等领域的未满足医疗需求，面向全球医疗市场开展业务。
ASTC vs CANF — 直观对比
营收规模更大
CANF
是对方的1.4倍
$148.0K
营收增速更快
CANF
高出7.2%
-43.3%
净利率更高
CANF
高出239.5%
-2653.4%
自由现金流更多
ASTC
多$799.0K
$-4.8M
损益表 — Q2 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.0K | $202.0K |
| 净利润 | $-3.9M | $-4.9M |
| 毛利率 | 5.4% | — |
| 营业利润率 | -2635.8% | -2424.8% |
| 净利率 | -2653.4% | -2413.9% |
| 营收同比 | -43.3% | -36.1% |
| 净利润同比 | 2.0% | -23.2% |
| 每股收益（稀释后） | — | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTCCANF
| Q4 25 | $148.0K | — | ||
| Q3 25 | $297.0K | — | ||
| Q2 25 | $220.0K | $202.0K | ||
| Q1 25 | $534.0K | — | ||
| Q4 24 | $261.0K | — | ||
| Q2 24 | — | $316.0K | ||
| Q4 23 | $1.1M | — | ||
| Q3 23 | $425.0K | — |
净利润ASTCCANF
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $-3.5M | — | ||
| Q2 25 | $-2.9M | $-4.9M | ||
| Q1 25 | $-3.6M | — | ||
| Q4 24 | $-4.0M | — | ||
| Q2 24 | — | $-4.0M | ||
| Q4 23 | $-2.6M | — | ||
| Q3 23 | $-2.9M | — |
毛利率ASTCCANF
| Q4 25 | 5.4% | — | ||
| Q3 25 | 63.3% | — | ||
| Q2 25 | 33.6% | — | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 59.4% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | 47.7% | — | ||
| Q3 23 | 43.1% | — |
营业利润率ASTCCANF
| Q4 25 | -2635.8% | — | ||
| Q3 25 | -1190.6% | — | ||
| Q2 25 | -1326.4% | -2424.8% | ||
| Q1 25 | -724.2% | — | ||
| Q4 24 | -1655.6% | — | ||
| Q2 24 | — | -1295.6% | ||
| Q4 23 | -275.2% | — | ||
| Q3 23 | -784.7% | — |
净利率ASTCCANF
| Q4 25 | -2653.4% | — | ||
| Q3 25 | -1166.7% | — | ||
| Q2 25 | -1331.8% | -2413.9% | ||
| Q1 25 | -680.3% | — | ||
| Q4 24 | -1536.0% | — | ||
| Q2 24 | — | -1252.2% | ||
| Q4 23 | -236.9% | — | ||
| Q3 23 | -685.2% | — |
每股收益（稀释后）ASTCCANF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | $0.00 | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.0M | $6.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $15.5M | $4.2M |
| 总资产 | $19.7M | $7.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASTCCANF
| Q4 25 | $7.0M | — | ||
| Q3 25 | $11.3M | — | ||
| Q2 25 | $15.1M | $6.5M | ||
| Q1 25 | $18.1M | — | ||
| Q4 24 | $21.5M | — | ||
| Q2 24 | — | $4.7M | ||
| Q4 23 | $52.4M | — | ||
| Q3 23 | $51.7M | — |
股东权益ASTCCANF
| Q4 25 | $15.5M | — | ||
| Q3 25 | $19.1M | — | ||
| Q2 25 | $22.1M | $4.2M | ||
| Q1 25 | $24.8M | — | ||
| Q4 24 | $28.1M | — | ||
| Q2 24 | — | $2.5M | ||
| Q4 23 | $40.3M | — | ||
| Q3 23 | $42.1M | — |
总资产ASTCCANF
| Q4 25 | $19.7M | — | ||
| Q3 25 | $23.2M | — | ||
| Q2 25 | $27.0M | $7.7M | ||
| Q1 25 | $27.5M | — | ||
| Q4 24 | $31.0M | — | ||
| Q2 24 | — | $5.9M | ||
| Q4 23 | $42.8M | — | ||
| Q3 23 | $44.6M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.5M | $-4.8M |
| 自由现金流经营现金流 - 资本支出 | $-4.0M | $-4.8M |
| 自由现金流率自由现金流/营收 | -2671.6% | -2353.0% |
| 资本支出强度资本支出/营收 | 277.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-14.9M | — |
8季度趋势，按日历期对齐
经营现金流ASTCCANF
| Q4 25 | $-3.5M | — | ||
| Q3 25 | $-3.9M | — | ||
| Q2 25 | $-2.4M | $-4.8M | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-3.0M | — | ||
| Q2 24 | — | $-4.0M | ||
| Q4 23 | $-1.8M | — | ||
| Q3 23 | $-3.0M | — |
自由现金流ASTCCANF
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-4.4M | — | ||
| Q2 25 | $-2.7M | $-4.8M | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-3.4M | — | ||
| Q2 24 | — | $-4.0M | ||
| Q4 23 | $-2.0M | — | ||
| Q3 23 | $-3.1M | — |
自由现金流率ASTCCANF
| Q4 25 | -2671.6% | — | ||
| Q3 25 | -1476.1% | — | ||
| Q2 25 | -1231.4% | -2353.0% | ||
| Q1 25 | -728.1% | — | ||
| Q4 24 | -1288.5% | — | ||
| Q2 24 | — | -1278.5% | ||
| Q4 23 | -175.2% | — | ||
| Q3 23 | -723.3% | — |
资本支出强度ASTCCANF
| Q4 25 | 277.7% | — | ||
| Q3 25 | 150.8% | — | ||
| Q2 25 | 158.2% | 0.5% | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 122.2% | — | ||
| Q2 24 | — | 1.3% | ||
| Q4 23 | 13.7% | — | ||
| Q3 23 | 5.6% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
